Get the timeout for the TCP idle connection. java.lang.String name() Get the name of the resource that is unique within the set of inbound NAT pools used by the load balancer. TransportProtocol protocol() Get the reference to the transport protocol used by the inbound NAT pool. ...
Static value InProgress for EvaluationState. static final EvaluationState NOT_STARTED Static value NotStarted for EvaluationState. Constructor Summary テーブルを展開する ConstructorDescription EvaluationState() Deprecated Use the fromString(String name) factory method. Creates a new instance of ...
COMPLETED public static final EvaluationState COMPLETED Static value Completed for EvaluationState.IN_PROGRESS public static final EvaluationState IN_PROGRESS Static value InProgress for EvaluationState.NOT_STARTED public static final EvaluationState NOT_STARTED Static value NotStarted for EvaluationState....
Applies to Azure SDK for Java LegacyCollabora con noi su GitHub L'origine di questo contenuto è disponibile in GitHub, in cui è anche possibile creare ed esaminare i problemi e le richieste pull. Per ulteriori informazioni, vedere la guida per i collaboratori. Feedback su Azure SDK ...
IsTabletPCKey Gets the ResourceKey for the IsTabletPC property. KanjiWindowHeight Gets a value that indicates the height, in pixels adjusted for DPI, of the kanji window at the bottom of the screen for systems that use double-byte characters. KanjiWindowHeightKey Gets the ResourceKey for th...
1月10日，和正医药/上海药物所共同宣布与强生签订全球许可协议，开发best-in-class BTK降解剂，用于治疗多种疾病。和正医药是一家以创新驱动技术为核心、处于临床阶段的小分子创新药物研发公司，致力于解决未满足的临床需求。公司独有的DaTProD 平台可用于开发具有差异化优势的蛋白降解新药产品，探索不可成药靶点，并...
See the example for CMap::Lookup.CMap::GetHashTableSizeDetermines the number of elements in the hash table for the map.Copy UINT GetHashTableSize() const; Return ValueThe number of elements in the hash table.ExampleC++ Copy CMap<int, int, CPoint, CPoint> myMap; UINT uTableSize = ...
1.35亿美元助力潜在“first-in-class”ADC开发，FDA接受RNAi疗法监管申请……转自：药明康德 开发潜在“first-in-class”抗体偶联药物，新锐完成1.35亿美元B轮融资 Adcendo公司今日宣布完成超额认购的1.35亿美元B轮融资，获得资金将用于推进该公司的潜在“first-in-class”抗体偶联药物（ADC）管线，包括ADCE-T02（...
OCS-05是一种新型拟肽小分子候选药物，有潜力成为用于急性视神经炎及其他神经眼科疾病的“first-in-class”神经保护疗法。在神经炎症和神经退行性动物模型中，OCS-05已显示出预防视网膜神经节细胞损伤的积极效果，并与运动能力改善相关。参考资料：[1] Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in ...
RGX-202是一种潜在“best-in-class”的基因疗法，旨在改善杜氏肌营养不良症患者的肌肉功能和预后。RGX-202的独特之处在于编码的微抗肌萎缩蛋白中包含了关键的C末端（CT）结构域，在临床前研究中，CT结构域已被证明可保护肌肉免受收缩引起的压力并改善其自我修复能力。（转自：药明康德）